• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Insulet (PODD) Rolls Out Omnipod Discover On A Narrative That May Still Be Undervalued

    Simply Wall St·10/20/2026 11:29:50
    Listen to the news

    Why Omnipod Discover’s rollout matters for Insulet stock

    Insulet (PODD) just moved Omnipod Discover from a limited program to a full U.S. launch, putting its data platform in front of every Omnipod 5 user and their care teams.

    The product ties weekly smartphone reports to real world glycemic data presented earlier this year, which linked user engagement with clinically meaningful time in range gains for roughly one third of tracked participants.

    Recent trading tells a mixed story for Insulet. The share price is at US$141.96 after a 1-day share price return of 0.61% and a 7-day share price return of 1.54%. However, momentum has faded over the past quarter, with a 90-day share price return that declined 13.29% and a year-to-date share price return that fell 49.82%. Longer term total shareholder return is also weak, with a 1-year decline of 56.57% and a 5-year total shareholder return that is down 53.02%.

    Scan beyond Insulet and see how other diabetes and medtech players with data driven platforms stack up in our hand picked list of 33 healthcare AI stocks.

    Insulet’s share slide and Omnipod Discover’s broader release point in opposite directions. Is this price more about the business on the ground, or a reset in sentiment that went too far, and how does that show up in valuation today?

    Most Popular Narrative: 15% Undervalued

    Insulet’s most followed narrative pegs fair value at $167.17, above the last close of $141.96. This view places more weight on Omnipod economics than on the recent share price.

    Scaling of the high margin recurring pod model, evidenced by Q2 2026 adjusted gross margin of 72.9% and adjusted operating margin expansion of 140 basis points year over year, suggests further manufacturing productivity and volume growth can support margin expansion and earnings growth even as customer support and R&D spending increase.

    See why 23 investors see Insulet as 15% undervalued.

    Result: Fair Value of $167.17 (UNDERVALUED)

    Still, the Insulet narrative rests on some fragile points, including weaker type 2 retention and utilization, as well as the overhang from the recent Class I recall and lawsuits.

    Find out about the key risks to this Insulet narrative.

    Next Steps

    If this combination of pressure and optimism around Insulet leaves you unsure, use the data to stress test your own thesis and promptly review the 3 key rewards.

    Looking for more investment ideas beyond Insulet?

    If Omnipod Discover has you thinking harder about where to put fresh capital, do not stop with Insulet. Broaden your watchlist before the next move leaves you reacting instead of ready.